Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors

Novel therapies are undergoing clinical trials, for example, the Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for the treatment of therapy‐resistant melanomas. Unfortunately, our data show that this combination elicits a heterogeneous response in a panel of melanoma cell lines includi...

Descripción completa

Detalles Bibliográficos
Autores principales: Azimi, Alireza, Caramuta, Stefano, Seashore‐Ludlow, Brinton, Boström, Johan, Robinson, Jonathan L, Edfors, Fredrik, Tuominen, Rainer, Kemper, Kristel, Krijgsman, Oscar, Peeper, Daniel S, Nielsen, Jens, Hansson, Johan, Egyhazi Brage, Suzanne, Altun, Mikael, Uhlen, Mathias, Maddalo, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836539/
https://www.ncbi.nlm.nih.gov/pubmed/29507054
http://dx.doi.org/10.15252/msb.20177858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836539/
https://www.ncbi.nlm.nih.gov/pubmed/29507054
http://dx.doi.org/10.15252/msb.20177858

Ejemplares similares